AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 182.37B -1.8% |
| Revenue (ttm) | 46.25B +8.6% |
| Net Income | 7.87B +25.9% |
| EPS | 5.03 +25.8% |
| Shares Out | 1.55B |
| PE Ratio | 23.35 |
| Forward PE | 14.67 |
| Dividend | 2.39 (2.00%) |
| Ex-Dividend Date | Aug 6, 2026 |
| Volume | 1,466,343 |
| Open | 11,810 |
| Previous Close | 11,758 |
| Day's Range | 11,708 - 11,960 |
| 52-Week Range | 10,524 - 15,732 |
| Beta | 0.20 |
| Analysts | Buy |
| Price Target | 15,746.06 (+34.49%) |
| Earnings Date | Oct 30, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is 15,746p, which is an increase of 34.49% from the latest price.
News
AstraZeneca says SERENA-4 trial did not meet primary objective
The company states: “The SERENA-4 Phase III trial of AstraZeneca’s (AZN) Etcamah (camizestrant) in combination with palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, did not meet the primary...
Stocks and Shares ISA returns by 2035: AZN merger cloud changes the maths
A Stocks and Shares ISA compounding at 9% a year can turn a £10,000 lump sum into roughly £21,000 by 2035, but the stock most often proposed as the engine for those returns, AstraZeneca (AZN), is now ...
AstraZeneca price target raised to 13,920 GBp from 13,750 GBp at HSBC
HSBC raised the firm’s price target on AstraZeneca (AZN) to 13,920 GBp from 13,750 GBp and keeps a Hold rating on the shares. The firm adjusted targets in the healthcare…
AstraZeneca Falls 1.3% Despite a 34% COPD Breakthrough
AstraZeneca Falls 1.3% Despite a 34% COPD Breakthrough
AZN Looks 12.5% Undervalued on GF Valueâ¢
AZN Looks 12.5% Undervalued on GF Valueâ¢
AstraZeneca drug reduces lung disease flare-ups in late-stage trials
Today we feature data from studies being presented at the ongoing European Respiratory Society Congress in Barcelona.
Lighting Round: I have never liked Grab Holdings, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stocks including: Joby Aviation, Simon Property Group, Grab Holdings, Trinity Industries, and AstraZeneca.
Cramer's lightning round: 'I am not going to put my money on AstraZeneca'
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
AstraZeneca initiated with an Outperform at RBC Capital
RBC Capital initiated coverage of AstraZeneca (AZN) with an Outperform rating and 14,500 GBp price target The firm believes AstraZeneca offers the most compelling risk/reward in European Union pharma....
AstraZeneca Falls Today Even as Imfinzi Wins a Landmark Survival Test
AstraZeneca Falls Today Even as Imfinzi Wins a Landmark Survival Test
Amgen And AstraZeneca's IMDELLTRA-Imfinzi Combo Shows Survival Benefit In Phase 3 ES-SCLC Study
(RTTNews) - Amgen Inc.(AMGN) on Tuesday reported that the Phase 3 DeLLphi-305 study, which evaluated IMDELLTRA (tarlatamab-dlle) in combination with AstraZeneca PLC's(AZN) Imfinzi (durvalumab) versus ...
AstraZeneca's Tozorakimab Shows Promise in COPD Trials, Stock Potential Soars
AstraZeneca's Tozorakimab Shows Promise in COPD Trials, Stock Potential Soars
AstraZeneca Transcript: Investor update
Tozorakimab demonstrated significant reductions in COPD exacerbations across all patient subgroups, supporting its potential as a first-in-class biologic for a broad population. With FDA priority review and a projected peak sales exceeding $5 billion, it is positioned to address a large unmet need and drive long-term growth alongside a robust pipeline.
AstraZeneca Slides: Investor update
AstraZeneca has posted slides in relation to its latest quarterly earnings report, which was published on September 8, 2026.
AZN Looks 10.1% Undervalued on GF Value⢠as Dividend Remains Attractive
AZN Looks 10.1% Undervalued on GF Value⢠as Dividend Remains Attractive
AstraZeneca Reports Positive Data For Tozorakimab From Phase III OBERON, TITANIA Trials In COPD
(RTTNews) - AstraZeneca PLC (AZN) announced positive results from the Phase III OBERON and TITANIA trials evaluating Tozorakimab in chronic obstructive pulmonary disease (COPD).
AZN Looks 10.1% Undervalued on GF Value⢠Amid Strong Dividend Sustainability
AZN Looks 10.1% Undervalued on GF Value⢠Amid Strong Dividend Sustainability
AstraZeneca Says Lung-Disease Drug Shows Benefits Across Patient Groups
AstraZeneca said its new drug for COPD showed benefits across a broad patient population in late-stage clinical trials, boosting a medicine the company expects to generate multibillion-dollar sales.
Amgen, AstraZeneca report Phase 3 DeLLphi-305 study met primary endpoint
Amgen (AMGN) announced results from the Phase 3 DeLLphi-305 study, which met its primary endpoint at a pre-specified interim analysis, demonstrating a statistically significant and clinically meaningf...
AstraZeneca's cancer drug combo hits main survival goal in late-stage trial
AstraZeneca said on Tuesday its cancer drug Imfinzi combined with Amgen's targeted immunotherapy Imdelltra significantly improved overall survival in first-line extensive-stage small cell l...
AstraZeneca announces results from Phase III trial of IMFINZI, tarlatamab
Positive high-level results from a planned interim analysis of the DeLLphi-305 Phase III trial showed IMFINZI plus Amgen’s (AMGN) tarlatamab demonstrated a statistically significant and highly clinica...
AstraZeneca’s COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
CNBC’s Annika Kim Constantino reports on the latest news on AstraZeneca.
AstraZeneca says tozorakimab demonstrates reduction in COPD exacerbations
Full results from the Phase III OBERON and TITANIA trials showed that tozorakimab is the first biologic to demonstrate statistically significant and highly clinically meaningful efficacy in reducing m...
Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials
WILMINGTON, Del.--(BUSINESS WIRE)--Full results from the positive Phase III OBERON and TITANIA trials showed that tozorakimab is the first biologic to demonstrate statistically significant and highly ...
AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
AstraZeneca released full results from two successful late-stage trials on its experimental drug for chronic obstructive pulmonary disease. The detailed data reinforces hopes that the product could be...